Empowering children and adolescents to adopt healthy lifestyles while tackling health inequalities is crucial. Person-centred interventions have been developed to this end but face several challenges: they are often restricted to one specific actor of children’s environment (teachers, parents, or peers) and rarely target several significant others simultaneously, they are often restricted to one specific behaviour (e.g., physical activity) or life domain (e.g., school), their effectiveness may differ according to socio-economic or socio-spatial conditions, and they are rarely both large-scale and personalised to individuals' needs. To address these challenges, and in line with the call, the ambition of YEAH! is to develop an innovative personalised person-centred digital intervention that: (1) promotes children (8-10 years) and adolescents’ (14-16 years) social interactions with multiple actors of their environment, (2) targets multiple health behaviours (physical activity, sedentary behaviours, diet, sleep), (3) combines in a novel manner evidence-based knowledge of optimal intervention features (theory-driven approach), with co-creation with end-users and stakeholders (data-driven approach) to tailor the intervention to the local context and target group, and (4) relies on a state-of-the-art method of intervention development to rigorously measure and verify its impact, optimise its sustainable implementation in the community and its equity, and evaluate its cost-effectiveness. To do so, YEAH!, which is coordinated by a woman researcher, will articulate interdisciplinary methods and concepts from psychology (health, social, developmental), public health, psychiatry, social marketing, geography, geomatics, environmental epidemiology, IT and computer sciences, statistics, physiology, and medicine, and on the participation of stakeholders (children and adolescents, parents, teachers, healthcare professionals, educators, local and national authorities).

280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depre280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who benefit from the current therapeutic journey. OPADE objective is to identify key biomarkers that support the decision-making process of the healthcare providers. The project focuses on the microbiota – brain -axis which plays a major role in mental health and in particular MDD. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks to: - Establish patient profiles to predict and optimise the efficacy of the antidepressants prescribed with an increase in the remission rate and reduction of impairment of real-life functioning, - Establish the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune-profile linked, epigenomic, enzymatic algorithms, - Evaluate molecular and non-molecular biomarkers that may represent predictive indices of recurrence - Discover new molecular targets for a personalised approach, - Improve the diagnostic accuracy for primary prevention, - Evaluate retrospectively, using accurate anamnesis, the onset of depressive symptoms in adolescence. - Establish how much and to what extent do blood biomarkers correlate with other specific biomarkers 350 patients between 14 and 50 years will be recruited in 6 EU and international countries for 24 months. Real-time EEG and patient cognitive assessment will be collected with blood, stool and saliva samples. Results and analysis will be used to train the AI / ML predictive tool, the main outcome of the project. A patient empowerment tool will be deployed over the project duration.